Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.

被引：0
|
作者：
Sholler, Giselle Linda Saulnier
Ferguson, William
Bergendahl, Genevieve
Clinch, Thomas
Kraveka, Jacqueline M.
机构：
[1] Penn State Hlth Childrens Hosp, Hershey, PA USA
[2] St Louis Univ, St Louis, MO 63103 USA
[3] US WorldMeds, Louisville, KY USA
[4] Med Univ South Carolina, Charleston, SC 29425 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10060
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy
    Zheng, Daniel J.
    Li, Anran
    Ma, Clement
    Ribeiro, Karina B.
    Diller, Lisa
    Bona, Kira
    Marron, Jonathan M.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (10)
  • [22] THE IMPACT OF POST-INDUCTION TREATMENT ON RESPONSE AND OUTCOMES OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA WITH REFRACTORY DISEASE.
    Siddiqui, A.
    Desai, A.
    Cohn, S.
    Gao, G.
    Oppong, A.
    Yuan, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S52 - S52
  • [23] Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings-Real-World Data
    Wieczorek, Aleksandra
    Zebrowska, Urszula
    Ussowicz, Marek
    Sokol, Agnieszka
    Stypinska, Marzena
    Dembowska-Baginska, Bozenna
    Pawinska-Wasikowska, Katarzyna
    Balwierz, Walentyna
    Barutello, Giuseppina
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (16)
  • [25] Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone
    Sokol, Elizabeth
    Haut, Paul R.
    Gosiengfiao, Yasmin
    Feinstein, Kate
    Pytel, Peter
    Cohn, Susan L.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (03) : 512 - 514
  • [26] A PHASE II PREVENTION TRIAL OF DFMO IN PATIENTS WITH HIGH RISK NEUROBLASTOMA IN REMISSION PREVENTS RELAPSE AND INCREASES EVENT FREE AND OVERALL SURVIVAL
    Sholler, Giselle
    Ferguson, William
    Bergendahl, Genevieve
    Bond, Jeffrey
    Roberts, William
    Eslin, Don
    Bredlau, Amy-Lee
    Oesterheld, Javier
    Mitchell, Deanna
    Foley, Jessica
    Parikh, Nehal
    Neville, Kathleen
    Wada, Randal
    Brown, Valerie
    Zage, Peter
    Eshun, Francis
    Rawwas, Jawhar
    Sencer, Susan
    Pankiewicz, Debra
    Quinn, Monique
    Kraveka, Jacqueline
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S7 - S7
  • [27] Overall survival and event free survival in patients with high-risk neuroblastoma after targeted therapy
    Mazankova, D.
    Mazanek, P.
    Maskova, V.
    Tinka, P.
    Kyr, M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1546 - 1546
  • [28] Iwilfin (eflornithine) approved by the FDA as the first and only oral maintenance therapy for high-risk neuroblastoma in adult and pediatric patients: Narrative review
    Shakeel, Ayesha
    Baloch, Aniqa
    Kumari, Versha
    Kazmi, Syeda Kainat Zehra
    Aftab, Kanza
    Abid, Shiza
    Syed, Amna
    Yousuf, Juvairia
    Hasanain, Muhammad
    Anjum, Muhammad Umair
    Mahmmoud Fadelallah Eljack, Mohammed
    MEDICINE, 2024, 103 (48)
  • [29] Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Eldridge, James
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Randomized Comparisons of Bevacizumab(B) and Irinotecan(I), Added to Temozolomide(T), In Children With Relapsed/Refractory High-Risk Neuroblastoma(RR-HRNB); Survival Results of the ITCC-SIOPEN Beacon-Neuroblastoma Phase 2 Trial
    Wheatley, K.
    Holt, G.
    Owens, C.
    Valteau-Couanet, D.
    Gambart, M.
    Castel, V.
    Van Eijkelenburg, N.
    Castellano, A.
    Nysom, K.
    Gerber, N.
    Laureys, G.
    Ladenstein, R.
    Makin, G.
    Vaidya, S.
    Thebaud, E.
    Kearns, P.
    Pearson, A.
    Moreno, L.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S31 - S31
12345